ALK and neuroblastoma: The identification of germline and somatic activating mutations in the tyrosine kinase domain of the Anaplastic Lymphoma Kinase (ALK) gene as well as amplification, rearrangments and/or over expression of either mutated or wild-type ALK alleles-revealed that such aberrations are oncogenic drivers in NB and correlate with worse patients' outcome or unfavourable aggressive NB phenotype [3–7].